Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
4.48 ^USD	-1.75%		-9.86%	+6.16%

Apr. 25	Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer	RE
Apr. 22	Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	MT

Vanda Pharmaceuticals : Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

September 07, 2021 at 08:31 pm EDT

WASHINGTON, Sept. 7, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16^th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021. Vanda management will host investor meetings. Vanda has updated its corporate presentation, which may be accessed on Vanda's website, www.vandapharma.com, by clicking on the Investors tab and following the Corporate Presentation link.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Corporate Contact:

AJ Jones II
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
(202) 734-3400
pr@vandapharma.com

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
(202) 734-3400
pr@vandapharma.com

View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-at-the-citi-16th-annual-biopharma-virtual-conference-301370818.html

SOURCE Vanda Pharmaceuticals Inc.

Latest news about Vanda Pharmaceuticals Inc.

Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer	Apr. 25	RE
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	Apr. 22	MT
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents	Apr. 22	RE
Butler Hall Capital urges Vanda to engage in sales discussions	Apr. 19	RE
Deals of the day-Mergers and acquisitions	Apr. 17	RE
Sector Update: Health Care Stocks Retreating Late Afternoon	Apr. 17	MT
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	Apr. 17	MT
Sector Update: Health Care	Apr. 17	MT
Top Midday Gainers	Apr. 17	MT
Vanda Pharmaceuticals Adopts Stockholder Rights Plan; Shares Rise	Apr. 17	MT
Vanda Pharmaceuticals' Board Rejects all Unsolicited Takeover Proposals From Future Pak	Apr. 17	MT
Vanda Pharmaceuticals rejects takeover proposal from Future Pak	Apr. 17	RE
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	Apr. 17	MT
Top Premarket Gainers	Apr. 17	MT
Vanda Pharmaceuticals Gets Acquisition Proposal From Future Pak; Shares Rise Pre-Bell	Apr. 17	MT
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., State Street Corporation, BlackRock, Inc., Dimensional Fund Advisors LP and others.	Apr. 16	CI
Top Midday Gainers	Apr. 03	MT
Vanda Pharmaceuticals Shares Soar After FDA Approval for Bipolar I Disorder Therapy	Apr. 03	MT
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket	Apr. 03	MT
Sector Update: Health Care Stocks Flat Pre-Bell Wednesday	Apr. 03	MT
Sector Update: Health Care	Apr. 03	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Bets Lean Towards Smaller Rate Cuts	Apr. 03	MT
Top Premarket Gainers	Apr. 03	MT
North American Morning Briefing : Powell Awaited as Inflation Fears Continue to Damp Mood	Apr. 03	DJ
Vanda Pharmaceuticals Secures FDA Approval for Bipolar I Disorder Therapy; Shares Rise Pre-Bell	Apr. 03	MT

Chart Vanda Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VANDA PHARMACEUTICALS INC.	+6.16%	258M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.79%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.21%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs

Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Vanda Pharmaceuticals : Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

Latest news about Vanda Pharmaceuticals Inc.

Chart Vanda Pharmaceuticals Inc.

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs